manilatimes

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and ...

New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- New York, Monday, November 3, 2025 - The Muscular Dystrophy Association (MDA) marks another milestone today in our legacy of progress with the FDA approval ...
WebMD

Kygevvi: FDA Approves First Oral Treatment for Thymidine Kinase 2 Deficiency (TK2d)

What Is Kygevvi, and Why Does It Matter? Kygevvi is a new oral medicine for people with thymidine kinase 2 deficiency (TK2d), an extremely rare genetic condition affecting the muscles. The FDA has ...
pharmaphorum

UCB brings first therapy for rare disease TK2d to EU

Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, after the European Commission cleared the drug "under exceptional ...
pharmaphorum

UCB drug for rare disease TK2d boosts survival

UCB's experimental medicine for rare disease thymidine kinase 2 deficiency (TK2d) has been shown to reduce the risk of death by a massive 95% in a study, as marketing applications are reviewed in the ...
Investing

FDA approves first treatment for rare genetic disease TK2d

ATLANTA - The U.S. Food and Drug Administration has approved KYGEVVI (doxecitine and doxribtimine) as the first treatment for thymidine kinase 2 deficiency (TK2d), UCB announced Monday. The ...
PharmiWeb

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

“The approval of doxecitine and doxribtimine represents a pivotal moment for the TK2d community who previously had no FDA-approved treatment options for this rare genetic mitochondrial disease beyond ...
GEN

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

Thymidine kinase 2 deficiency (TK2d) is an ultra-rare (1.64 cases per 1,000,000 people) often fatal, genetic mitochondrial disease characterized by progressive and severe muscle weakness. Those ...
Mena FN

FDA Approves KYGEVVI® (Doxecitine And Doxribtimine), The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d), A Rare And ...

(MENAFN- GlobeNewsWire - Nasdaq) This novel therapy offers the first FDA-approved option to address the root cause of this ultra-rare condition, which causes progressive muscle weakness impairing ...
Finanznachrichten

UCB: U.S. FDA approves KYGEVVI (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Approved indication: KYGEVVI ® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients ...